Good morning. If you’re just waking up, $AMRN is trading at $10. That a 200%-plus move. Grab some coffee and read: https://t.co/P53RVTKNM8— Adam Feuerstein (@adamfeuerstein) September 24, 2018
AbbVie accused of paying kickbacks, using a stealthy network to promote Humira $ABBV | https://t.co/aH8W0nKjTX pic.twitter.com/3A5Mpf8A61— medtech[y] (@medtechy) September 19, 2018
In a bid to appeal to millennials, Botox-maker Allergan is asking them if they're 'bo-curious' $AGN | https://t.co/wRRVttWrwQ pic.twitter.com/IZQJO0Yee8— medtech[y] (@medtechy) September 17, 2018
According to WSJ reporter, John Carreyrou, the blood-testing company,Theranos, has emailed shareholders and has decided to shut the company down. ...
MannKind's stock ($MNKD) is up 51% in midday trading as they have entered into a worldwide exclusive licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil...
Bausch Health's core business is executing at a healthy clip, delivering 78% of the company's revenue in their most recent quarterly earnings. When breaking this down, Bausch & Lomb was 57% and Salix was 21% of the business. When combined, these segments represented organic growth of 6%. ...
Doctors Aren't Being Candid About the Money They Get From Big #Pharma https://t.co/f2Oj2A7fjY pic.twitter.com/YFNFLAGqt3— medtech[y] (@medtechy) August 16, 2018
EpiPen will get generic competition https://t.co/9dxJ4gC0Yl— Bloomberg (@business) August 16, 2018
$MNKD Q2— Adam Feuerstein (@adamfeuerstein) August 2, 2018
Afrezza revenue: $3.8M
Mannkind is the MoviePass of biotech.
GlaxoSmithKline is partnering with 23andMe to develop new medicines. The companies will split costs and profits equally, and Glaxo will make a $300 million investment in 23andMe https://t.co/5ipyBHXJnA by @matthewherper pic.twitter.com/VaJGCDqwmw— Forbes Health (@forbeshealth) July 25, 2018